Home » Newsletters » BioWorld Science

BioWorld Science

June 9, 2011

View Archived Issues

New clinical data presented on LY-2127399 in rheumatoid arthritis and multiple myeloma

Interim data from first-in-human trial of Pfizer's CVX-241 support safety in advanced solid tumors

Anacor Pharmaceuticals claims new boron-containing antibacterials

Merck & Co. synthesizes novel histamine H3 receptor antagonists

Concert Pharmaceuticals presents new inhibitors of V600E-mutated B-raf

Novel inhibitors of HIF1-alpha synthesized by Elara Pharmaceuticals

Yokukansan reduces delirium after acute ischemic stroke

LGD-4033 well tolerated in healthy volunteers at multiple doses

Dainippon Sumitomo Pharma and University of Tokyo expand collaboration for CD5 antigen-like

Topline phase IIb data reported on vidofludimus in rheumatoid arthritis

Merck & Co. and Roche to apply Roche's diagnostic assays to Merck & Co.'s anticancer portfolio

New clinical data presented on lurasidone in schizophrenia

Hyaluronic acid as a biomarker of lung cancer diagnosis and prognosis

New HCV NS5A inhibitors patented by Bristol-Myers Squibb

PROLOR reports encouraging preclinical results on OXY-RPEG

Enrollment begins in first-in-human TOCA-511 trial in high-grade glioma

FDA approves Eli Lilly's sNDA with updates to Humalog label

Halozyme and Intrexon sign licensing agreement to develop subcutaneous rHuA1AT formulation

Neuralstem and Summit Pharmaceuticals sign license agreement for NSI-189 in Japan

Quest PharmaTech provides update on oregovomab trial

Health Canada approves new expanded indication for Mezavant

Antisense Therapeutics raises funds to conduct additional studies of ATL-1103

XOMA provides 6-month topline results from phase IIa XOMA-052 trial in type 2 diabetes

Vaxart starts phase I trial of oral vaccine against H5N1 flu

Neurologix discloses new data from phase II trial of NLX-P101 in Parkinson's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...